KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short term Debt (2016 - 2025)

Travere Therapeutics' Short term Debt history spans 13 years, with the latest figure at $68.8 million for Q2 2025.

  • For Q2 2025, Short term Debt changed N/A year-over-year to $68.8 million; the TTM value through Jun 2025 reached $68.8 million, changed N/A, while the annual FY2024 figure was $68.7 million, N/A changed from the prior year.
  • Short term Debt reached $68.8 million in Q2 2025 per TVTX's latest filing, roughly flat from $68.8 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $68.8 million in Q2 2025 to a low of $6.9 million in Q1 2023.
  • Average Short term Debt over 5 years is $29.6 million, with a median of $7.4 million recorded in 2021.
  • Peak YoY movement for Short term Debt: plummeted 57.47% in 2021, then decreased 5.41% in 2022.
  • A 5-year view of Short term Debt shows it stood at $7.4 million in 2021, then fell by 5.41% to $7.0 million in 2022, then fell by 1.43% to $6.9 million in 2023, then skyrocketed by 895.33% to $68.7 million in 2024, then increased by 0.23% to $68.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Short term Debt are $68.8 million (Q2 2025), $68.8 million (Q1 2025), and $68.7 million (Q4 2024).